Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes

Chemical Research in Toxicology

Volumn 25, Issue 5, 2012, Pages 1145-1154

  Koen, Yakov M ^a   Sarma, Diganta ^a   Williams, Todd D ^a   Galeva, Nadezhda A ^a   Obach, R Scott ^b   Hanzlik, Robert P ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CELL PROTEIN; DRUG METABOLITE; FUMARYLACETOACETASE; TIENILIC ACID;

AMINO ACID SEQUENCE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIVER CELL; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN TARGETING; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEPATOCYTES; HUMANS; PROTEINS; TANDEM MASS SPECTROMETRY; TICRYNAFEN;

RATTUS;

EID: 84861322285     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx300103j     Document Type: Article

References (67)

1. Methogo, R., Dansette, P., and Klarskov, K. (2007) Int. J. Mass Spectrom., 268, 284 -295
2. Meanwell, N. (2011) Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 24, 1420-1456
3. Johnson, W. W. (2008) Many drugs and phytochemicals can be activated to biological reactive intermediates Curr. Drug Metab. 9, 344-351
4. Kaplowitz, N. (2005) Idiosyncratic hepatotoxicity Nat. Rev. Drug Discovery 4, 489-499
5. Walgren, J. L., Mitchell, M. D., and Thompson, D. C. (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity Crit. Rev. Toxicol. 35, 325-361
6. Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., and Okazaki, O. (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 37, 1970-1977
7. Obach, R. S., Kalgutkar, A. S., Soglia, J. R., and Zhao, S. X. (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose CRC Crit. Rev. Toxicol. 21, 1814-1822
8. Takakusa, H., Masumoto, H., Yukinaga, H., Makino, C., Nakayama, S., Okazaki, O., and Sudo, K. (2008) Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity Drug Metab. Dispos. 36, 1770-1779
9. Usui, T., Mise, M., Hashizume, T., Yabuki, M., and Komuro, S. (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins Drug Metab. Dispos. 37, 2383-2392
10. Roth, R. A. and Ganey, P. E. (2011) Animal models of idiosyncratic drug-induced liver injury: current status Crit. Rev. Toxicol. 1-17
11. Uetrecht, J. (2009) Immune-mediated adverse drug reactions Chem. Res. Toxicol. 22, 24-34
12. Zimmerman, H. J., Lewis, J. H., Ishak, K. G., and Maddrey, W. C. (1984) Ticrynafen-associated hepatic injury: Analysis of 340 cases Hepatology 4, 315-323
13. Park, B. K., Laverty., H., Srivastava, A., Antoine, D. J., Naisbitt, D., and Williams, D. P. (2011) Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity Chem.-Biol. Interact. 192, 30-36
14. 2) in tienilic acid-induced hepatitis Clin. Exp. Imunol. 55, 561-570
15. Mansuy, D. (1997) Molecular structure and hepatotoxicity: Compared data about two closely related thiophene compounds J. Hepatol. 26 (Suppl. 2) 22-25
16. Neuberger, J. and Williams, R. (1989) Immune mechanisms in tienilic acid associated hepatotoxicity Gut 30, 515-519
17. Lopez-Garcia, M. P., Dansette, P. M., and Mansuy, D. (1994) Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: Inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid Biochemistry 33, 166-175
18. Koenigs, L. L., Peter, R. M., Hunter, A. P., Haining, R. L., Rettie, A. E., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., and Trager, W. F. (1999) Electrospray ionization mass spectrometric analysis of intact cytochrome P450: Identification of tienilic acid adducts to P450 2C9 Biochemistry 38, 2312
19. Lecoeur, S., Bonierbale, E., Challine, D., Gautier, J.-C., Valadon, P., Dansette, P. M., Catinot, R., Ballet, F., Mansuy, D., and Beaune, P. H. (1994) Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: Comparison with two directly hepatotoxic drugs Chem. Res. Toxicol. 7, 434-442
20. Lopez-Garcia, M. P., Dansette, P. M., and Coloma, J. (2005) Kinetics of tienilic acid bioactivation and functional generation of drug-protein adducts in intact rat hepatocytes Biochem. Pharmacol. 70, 1870-1882
21. Bonierbale, E., Valadon, P., Pons, C., Desfosses, B., Dansette, P. M., and Mansuy, D. (1999) Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: Use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds Chem. Res. Toxicol. 12, 286-296
22. Zimmerman, H. J., Abernathy, C. O., Lukacs, L., and Ezekiel, E. (1982) Effects of ticrynafen on hepatic excretory function in the isolated perfused rat liver Hepatology 2, 255-257
23. Nishiya, T., Kato, M., Suzuki, T., Maru, C., Kataoka, H., Hattori, C., Mori, K., Jindo, T., Tanaka, Y., and Manabe, S. (2008) Involvement of cytochrome P450-mediated metabolism in tienilic acid hepatotoxicity in rats Toxicol. Lett. 183, 81-19
24. Belghazi, M., Jean, P., Poli, S., Schmitter, J.-M., Mansuy, D., and Dansette, P. M. (2001) Use of isotopes and LC-MS-ESI-TOF for mechanistic studies of tienilic acid metabolic activation Adv. Exp. Med. Biol 500, 139-144
25. Masubuchi, N., Makino, C., and Murayama, N. (2007) Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediates: Correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans Chem. Res. Toxicol. 20, 455-464
26. Mansuy, D., Valadon, P., Erdelmeier, I., Lopez-Garcia, M. P., Amar, C., Girault, J.-P., and Dansette, P. M. (1991) Thiophene S -oxides as new reactive metabolites: Formation by cytochrome P450 dependent oxidation and reaction with nucleophiles J. Am. Chem. Soc. 113, 7825-7826
27. Dansette, P. M., Amar, C., Smith, C., Pons, C., and Mansuy, D. (1990) Oxidative bioactivation of the thiophene ring by hepatic enzymes Biochem. Pharmacol. 39, 911-918
28. Valadon, P., Dansette, P. M., Girault, J.-P., Amar, C., and Mansuy, D. (1996) Thiophene sulfoxides as reactive metabolites: Formation upon microsomal oxidation of a 3-aroylthiophene and fate in the presence of nucleophiles in vitro and in vivo Chem. Res. Toxicol. 9, 1402-1413
29. Dansette, P. M., Amar, C., Valadon, P., Pons, C., Beaune, P. H., and Mansuy, D. (1991) Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes Biochem. Pharmacol. 41, 553-560
30. Lopez-Garcia, M. P., Dansette, P. M., Valadon, P., Amar, C., Beaune, P. H., Guengerich, F. P., and Mansuy, D. (1993) Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cyrochromes P-450 2C9 and 2C10 Eur. J. Biochem. 213, 223-232
31. Beaune, P. H., Dansette, P. M., Mansuy, D., Kiffel, L., Finck, M., Leroux, J. P., and Homberg, J. P. (1987) Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P450 that hydroxylates the drug Proc. Natl. Acad. Sci. U.S.A. 84, 551-555
32. Jean, P., Lopez-Garcia, M. P., Dansette, P. M., Mansuy, D., and Goldstein, J. L. (1996) Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19 Eur. J. Biochem. 241, 797-804
33. Hutzler, J. M., Balogh, L. M., Zientek., M., Kumar, V., and Tracy, T. S. (2009) Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (±)-suprofen: A comparison of kinetics and probe substrate selection Drug Metab. Dispos. 37, 59-65
34. O'Donnell, J. P., Dalvie, D. K., Kalgutkar, A. S., and Obach, R. S. (2003) Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflamatory drug suprofen Drug Metab. Dispos. 31, 1369-1367
35. Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N., Okazaki, O., Ikeda, T., and Kurihara, A. (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab. Dispos. 38, 92-99
36. Pereillo, J.-M., Maftouh, M., Adrieu, A., Uzabiaga, M.-F., Fedeli, O., Savi, P., Pascal, M., Herbert, J.-M., Maffrand, J.-P., and Picard, C. (2002) Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab. Dispos. 30, 1288-1295
37. Dansette, P. M., Rosi, J., Bertho, G., and Mansuy, D. (2011) Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite iisomer Chem. Res. Toxicol. 25, 348-356
38. Alvarez, F. J. and Slade, R. T. (1992) Kinetics and mechanism of degradation of zileuton, a potent 5-lipoxygenase inhibitor Pharm. Res. 9, 1465-1473
39. Li, F., Chordia, M. D., Woodling, K. A., and Macdonald, T. L. (2007) Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene S -oxide: A potential model for hepatotoxicity Chem. Res. Toxicol. 20, 1854-1861
40. Joshi, E. M., Heasley, B. H., and Macdonald, T. L. (2009) 2-Abt- S -oxide detoxification by glutathione S -transferases A1-1, M1-1 and P1-1: Implications for toxicity associated with zileuton Xenobiotica 39, 197-204
41. Joshi, E. M., Heasley, B. H., Chordia, M. D., and Macdonald, T. L. (2004) In vitro metabolism of 2-acetylbenzothiophene: Relevance to zileuton hepatotoxicity Chem. Res. Toxicol. 17, 137-143
42. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein covalent adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 17, 3-16
43. Reactive Metabolite Target Protein Database, http://tpdb.medchem.ku.edu: 8080/protein-database/.
44. Methogo, R., Dansette, P., and Klarskov, K. (2007) Identification of liver protein targets modified by tienilic acid metabolites using a two-dimensional western blot-mass spectrometry approach Int. J. Mass Spectrom. 268, 284-295
45. Ji, T., Ikehata, K., Koen, Y. M., Esch, S. W., Williams, T. D., and Hanzlik, R. P. (2007) Covalent modification of microsomal lipids by thiobenzamide metabolites in vivo Chem. Res. Toxicol. 20, 701-708
46. Koen, Y. M., Gogichaeva, N. V., Alterman, M. A., and Hanzlik, R. P. (2007) A proteomic analysis of bromobenzene reactive metabolite targets in rat liver cytosol in vivo Chem. Res. Toxicol. 20, 511-519
47. Koen, Y. M. and Hanzlik, R. P. (2002) Identification of seven proteins in the endoplasmic reticulum as targets for reactive metabolites of bromobenzene Chem. Res. Toxicol. 15, 699-706
48. Koen, Y. M., Williams, T. D., and Hanzlik, R. P. (2000) Identification of three protein targets for reactive metabolites of bromobenzene in rat liver cytosol Chem. Res. Toxicol. 13, 1326-1335
49. Ikehata, K., Duzhak, T., Galeva, N. A., Ji, T., Koen, Y. M., and Hanzlik, R. P. (2008) Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo Chem. Res. Toxicol. 21, 1432-1442
50. Keller, A., Nesvizhskii, A. I., Kolker, E., and Aebersold, R. H. (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by ms/ms and database search Anal. Chem. 74, 5383-5392
51. Galeva, N. A. and Alterman, M. A. (2002) Comparison of one-dimensional and two-dimensional gel elecrophoresis as a separation tool for proteomic analysis of rat liver microsomes: Cytochromes P450 and other membrane proteins Proteomics 2, 713-722
52. Meier, B. W., Gomez, J. D., Kirichenko, O. V., and Thompson, J. A. (2007) Mechanistic basis for inflammation and tumor promotion in lungs of 2,6-di- tert- butyl-4-methylphenol-treated mice: Electrophilic metabolites alkylate and inactivate antioxidant enzymes Chem. Res. Toxicol. 20, 199-207
53. Qiu, Y., Burlingame, A. L., and Benet, L. Z. (1998) Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry J. Biol. Chem. 273, 17940-17953
54. Zhang, X., Yang, J., Guo, Y., Ye, H., Yu, C., Xu, C., Wu, S., Sun, W., Wei, H., Gao, X., Zhu, Y., Qian, Z., Jiang, Y., Li, Y., and He, F. (2010) Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: Enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis Hepatology 51, 1190-1199
55. McMahon, B. and Murray, P. T. (2010) Urinary liver fatty acid-binding protein: Another novel biomarker of acute kidney disease Kidney Internat. 77, 657-659
56. Kamiho-Ikemori, A., Sugaya, T., Matsui, K., Yokoyama, T., and Kimura, K. (2011) Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosamal transgenic mice Nephrology 16, 539-544
57. Kunzendorf, U., Haase, M., Rölver, L., and Haase-Fielitz, A. (2010) Novel aspects of pharmacological therapies for acute renal failure Drugs 70, 1099-1114
58. Colombo, E., Alcalay, M., and Pelicci, P. G. (2011) Nucleophosmin and its complex network: A possible therapeutic target in hematological diseases Oncogene 30, 2595-2609
59. Okuwaki, M. (2008) The structure and functions of NPM/nucleophosmin/B23, a multifunctional nucleolar acidic protein J. Biochem. (Tokyo) 143, 441-448
60. Mörbt, N., Tomm, J., Feltens, R., Mögel, I., Kalkhof, S., Murugesan, K., Wirth, H., Vogt, C., Binder, H., Lehman, I., and von Bergen, M. (2011) Chlorinated benzenes cause concomitantly oxidative stress and induction of apoptotic markers in lung epithelian cells (A549) at nonacute toxic concentrations J. Proteome Res. 10, 363-378
61. Townsend, D. M., Findlay, V. J., Fazilev, F., Ogle, M., Fraser, J., Saavedra, J. E., Ji, X., Keefer, L. K., and Tew, K. D. (2006) A glutathione S-transferase π-activated prodrug causes kinase activation concurrent with S -glutathionylatioin of proteins Mol. Pharmacol. 69, 501-508
62. Granovsky, A. and Rosner, M. R. (2008) Raf kinase inhibitory protein: A signal transduction modulator and metastasis suppressor Cell Res. 18, 452-457
63. Klysik, J., Theroux., S. J., Sedivy, J. M., Moffit, J. S., and Boekelheide, K. (2008) Signaling crossroads: The function of raf kinase inhibitory protein in cancer, the central nervous system and reproduction Cell. Signalling 20, 1-9
64. Zeng, L., Imamoto, A., and Rosner, M. R. (2008) Raf kinase inhibitory protein (RKIP): A physiological regulator and future therapeutic target Expert Opin. Ther. Targets 12, 1275-1287
65. Artal-Sanz, M. and Tavernarakis, N. (2009) Prohibitin and mitochondrial biology Trends Endocrinol. Metab. 20, 394-401
66. Mishra, S., Ande, S. R., and Nyomba, B. L. G. (2010) The role of prohibitin in cell signaling FEBS J. 277, 3937-3946
67. Theiss, A. L. and Sitaraman, S. V. (2011) The role and therapeutic potential of prohibitin in disease Biochim. Biophys. Acta 1813, 1137-1143